In a study by Liao et al. KRAS mutation was found to direct the tumour recruitment of myeloid derived suppressor cells through the IRF2-CXCL3-CXCR2 axis leading to immune therapy resistance in CRC [39]. This evidence concerns the gene KRAS and neoplasm.